Founded in 2015 as a spin-off of the University of Basel, T3 Pharmaceuticals is dedicated to improving the lives of cancer patients by developing highly specific and efficient treatments using live bacteria. The company has developed an efficient protein delivery technology based on the use of live bacteria, which has diverse applications in research. T3 Pharma has further developed this system to serve as a novel therapeutic for treating solid tumors, addressing the high need for innovative medicines in cancer treatment.